Over the last decade, the only new treatment for Alzheimer’s to make it to market is memantine (Namenda™).  The number of failed drug programs in that span provides a roadmap of scientific approaches that initially appear promising, but flame out in late-stage development.  Most recently, two encouraging drugs, bapineuzimab (Pfizer/Janssen) and solanezumab (Lilly), completed large Phase III programs, only failed to meet the designated endpoints necessary for approval.  Thomas E. Zoda of INC Research asks: is there a better way?